Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · IEX Real-Time Price · USD
1.080
+0.050 (4.85%)
At close: May 1, 2024, 4:00 PM
1.070
-0.010 (-0.93%)
After-hours: May 1, 2024, 7:30 PM EDT
Karyopharm Therapeutics Revenue
In the year 2023, Karyopharm Therapeutics had annual revenue of $146.03M, a decrease of -7.03%. Revenue in the quarter ending December 31, 2023 was $33.75M with 0.50% year-over-year growth.
Revenue (ttm)
$146.03M
Revenue Growth
-7.03%
P/S Ratio
0.86
Revenue / Employee
$449,332
Employees
325
Market Cap
125.78M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
Dec 31, 2011 | 152.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amylyx Pharmaceuticals | 380.79M |
Outset Medical | 130.38M |
Seer, Inc. | 16.66M |
DBV Technologies | 15.73M |
Vaxart | 7.38M |
Omega Therapeutics | 3.09M |
Delcath Systems | 2.07M |
VistaGen Therapeutics | 1.04M |
KPTI News
- 7 days ago - Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PRNewsWire
- 4 weeks ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences - PRNewsWire
- 2 months ago - Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 2 months ago - Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 - PRNewsWire
- 4 months ago - Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives - PRNewsWire
- 4 months ago - Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 months ago - Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List - PRNewsWire